Lettre Trimestrielle T3 2015

Cliquez ici pour télécharger la troisième Lettre Trimestrielle de Trecento

#Kadcyla (HER2-positive early #breast #cancer) from #Genentech (#Roche unit) met primary endpoint in a Ph III study… https://t.co/YpSjAHlTOU

Club Trecento Santé @Trecento_Sante October 15, 2018

@genentech (filiale de @Roche) a annoncé des résultats positifs en Ph III pour le #Kadcyla (#cancer du #sein HER-2… https://t.co/hv58Kws4Z4

Club Trecento Santé @Trecento_Sante October 15, 2018

#Capio recommended shareholders to accept #RamsayGDS new takeover price at 58SEK per share (+20% from the previous… https://t.co/scqePlFGlW

Club Trecento Santé @Trecento_Sante October 10, 2018

#Capio semble se satisfaire de la révision à la hausse de l'offre d'achat par @RamsayGDS (58 SEK par action) et rec… https://t.co/zDTZZUTfp8

Club Trecento Santé @Trecento_Sante October 10, 2018

#RamsayGDS increases #CAPIO offer price by almost 20% at 58 SEK per share, versus 48.5 #M&A #Healthcare #Services… https://t.co/uisxxeAnaM

Club Trecento Santé @Trecento_Sante October 8, 2018

@RamsayGDS relève son offre sur #CAPIO de près de 20% à 58 SEK par action, contre 48,5 précédemment… https://t.co/ym0Hb6UEXL

Club Trecento Santé @Trecento_Sante October 8, 2018

#Roche won #US_FDA regulatory approval to sell #Hemlibra (#emicizumab) to the largest portion of #hemophilia patien… https://t.co/2g1ceoWFcv

Club Trecento Santé @Trecento_Sante October 5, 2018

@Roche obtient le feu vert de la @US_FDA pour la commercialisation d'#Hemlibra (#emicizumab) auprès du plus large g… https://t.co/d6RugV9FBu

1 1

Club Trecento Santé @Trecento_Sante October 5, 2018

Positive results in a Ph III study for the #Baloxavir #marboxil from #Roche, which aims to treat #Flu patients at r… https://t.co/VNPZRFBWQp

Club Trecento Santé @Trecento_Sante October 4, 2018

Données positives en Ph III pour le #Baloxavir #marboxil de @Roche destiné à traiter les patients atteints de la… https://t.co/IdRp9AMaMJ

1 2

Club Trecento Santé @Trecento_Sante October 4, 2018

#Sanofi completes sale of its #Generics division to #Advent International for about 1.9 billion of euros. The Compa… https://t.co/F5tc2EZJDu

Club Trecento Santé @Trecento_Sante October 1, 2018

@sanofi finalise la cession de sa division #Génériques à #Advent International (Private Equity) pour 1,9 milliard d… https://t.co/lG4Mw8PEUM

Club Trecento Santé @Trecento_Sante October 1, 2018

@AlexionPharma to buy #Symtimmune, biotech company which currently has a treatment for autoimmune hemolytic anemia… https://t.co/1gmWqea2i7

Club Trecento Santé @Trecento_Sante September 26, 2018

@AlexionPharma rachète #Symtimmune, biotech développant notamment un traitement pour l'#anémie hémolytique auto-imm… https://t.co/yY0yZxaVvD

Club Trecento Santé @Trecento_Sante September 26, 2018

At #TCT2018, manufacturers of #cardiologic medical equipment have demonstrated improvements in their equipment and… https://t.co/gsxWH3pn05

Club Trecento Santé @Trecento_Sante September 25, 2018

Au #TCT2018, les fabricants d'équipements médicaux en #cardiologie ont fait la démonstration d'améliorations de leu… https://t.co/fJ2s8EyeZP

4 4

Club Trecento Santé @Trecento_Sante September 25, 2018

Diabetics are at increased risk of heart problems, making the #cardiovascular (CV) profile of medicines to treat th… https://t.co/sfW3ABUzbc

Club Trecento Santé @Trecento_Sante September 24, 2018

La prise en compte des événements #cardiovasculaires dans les traitements contre le #diabète devient de plus en plu… https://t.co/gF9mDxk3Na

1 2

Club Trecento Santé @Trecento_Sante September 24, 2018

RT @Trecento_Robot: @Medtronic rachète @MazorRobotics, spécialiste des #robots #chirurgicaux dans le domaine interventionnel de la #colonne…

Club Trecento Santé @Trecento_Sante September 21, 2018

According to sources familiar with the matter, #Nestlé, #Unilever and #Coca-Cola could buy #Horlicks, a nutrition b… https://t.co/JzJOJJ5oQ5

Club Trecento Santé @Trecento_Sante September 19, 2018

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Toujours activé

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Durée	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Lettre Trimestrielle T3 2015

Articles similaires